GlassScriptPhysician profile
Joseph Raymond Murphy
NPI 1174521173
$3,138.59
in general payments reported to CMS, 2019-2025
24 companies · $634 in 2025
The $634 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $312 · 2021: $250 · 2022: $316 · 2023: $543 · 2024: $629 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,806.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $958.15 | 2019-2025 | |
| Janssen Biotech, INC. | $399.59 | 2020-2025 | Stelara, Tremfya, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $303.59 | 2019-2025 | Entyvio |
| Pfizer INC. | $263.93 | 2019-2025 | |
| Celgene Corporation | $250.61 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.84 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $130.46 | 2020-2023 | |
| Ardelyx, INC. | $109.55 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $74.84 | 2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $71.86 | 2019-2021 | |
| Vivus LLC | $66.60 | 2020 | |
| Genzyme Corporation | $60.13 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $52.94 | 2019 | |
| Ucb, INC. | $40.28 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $32.59 | 2022-2023 | Dupixent |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $30.87 | 2025 | Voquezna |
| Braintree Laboratories, INC. | $27.43 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $25.15 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.29 | 2023 | Cyltezo |
| Novo Nordisk INC | $21.08 | 2025 | Wegovy |
| Allergan, INC. | $15.65 | 2019 | |
| Merck Sharp & Dohme LLC | $15.29 | 2024 | Bridion |
| Nestle Healthcare Nutrition INC. | $14.36 | 2021 | |
| Capsovision, INC. | $13.51 | 2024 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.